FOLH1 and neoplasm: However, based on the mode of action and in concordance to results from our pilot study (clinicaltrials.gov identifier: NCT03828838), 177Lu-PSMA is also highly effective in low volume disease because of high tumor uptake of PSMA targeted radioligands in small lesions, such as oHSPC [27–29].